Table 1.

Validation of IL-6 responsive genes in human skeletal muscle

Gene	Treatment	0 h (a.u.)	3 h (a.u.)	6 h (a.u.)	Main effect
FKBP5	IL-6	2.18 (0.79–3.57)#	3.22 (1.83–4.61)	3.46 (2.07–4.85)	Time, P < 0.0001
	Con	0.64 (−0.75–2.03)	2.68 (1.29–4.07)***	3.61 (2.22–5.00)***	Time × Treat, P < 0.01
HDAC4	IL-6	1.47 (0.85–2.08)	2.11 (1.50–2.73)	3.24 (2.62–3.85)*	Time, P < 0.01
	Con	1.54 (0.93–2.16)	1.68 (1.06–2.29)	1.99 (1.37–2.01)
HDAC9	IL-6	2.92 (2.28–3.57)	1.25 (0.61–1.90)	1.23 (0.59–1.88)	Time, P < 0.0001
	Con	3.09 (2.44–3.73)	2.18 (1.53–2.82)	1.36 (0.71–2.00)**
MEF2A	IL-6	1.54 (0.87–2.20)	1.55 (0.89–2.22)	1.75 (1.09–2.42)
	Con	1.88 (1.22–2.55)	1.72 (1.06–2.39)	1.77 (1.11–2.44)
PPM2C	IL-6	3.20 (2.29–4.11)	1.47 (0.55–2.38)*	1.57 (0.66–2.48)*	Time, P < 0.0001
	Con	5.11 (4.19–6.01)	3.34 (2.42–4.24)	2.05 (1.14–2.96)***	Treat, P < 0.05
S100A8	IL-6	1.30 (0.30–2.30)	4.14 (3.14–5.14)***###	2.60 (1.59–3.60)	Time, P < 0.01,Treat,P < 0.01
	Con	1.76 (0.75–2.76)	1.10 (0.09–2.10)	1.37 (0.37–2.37)	Time × Treat, P < 0.01
UCP3	IL-6	1.22 (0.62–1.82)	1.51 (0.91–2.11)	1.99 (1.39–2.59)
	Con	1.63 (1.03–2.23)	1.71 (1.11–2.31)	1.63 (1.03–2.23)
USP2	IL-6	2.94 (2.08–3.80)	2.19 (1.32–3.05)	2.34 (1.48–3.20)	Time × Treat, P < 0.05
	Con	2.03 (1.16–2.89)	2.80 (1.94–3.66)	2.24 (1.38–3.10)

RT-PCR results of selected genes on human subjects treated with IL-6 versus controls (con). FKBP5: FK506 binding protein 5; HDAC4: histone deacetylase 4; HDAC9: histone deacetylase 9; PPM2C: protein phosphatase 2C, magnesium-dependent, catalytic subunit; S100A8: S100 calcium binding protein A8 (calgranulin A); UCP3: uncoupling protein 3; USP2: ubiquitin specific protease 2. All values are shown as means with 95% confidence intervals in arbitrary units (a.u.).

^*P < 0.05 versus 0 h time point,

^**P < 0.01 versus 0 h time point,

^***P < 0.001 versus 0 h time point.

^#P < 0.05 versus control at the same time point,

^###P < 0.001 versus control at the same time point.